Late-onset Pneumocystis jirovecii pneumonia in solid organ transplant recipients

Transplant Infectious Disease

Volumn 16, Issue 2, 2014, Pages 324-328

  Perez Ordono L ^a   Hoyo, I ^a   Sanclemente, G ^a   Ricart, M J ^a   Cofan, F ^a   Perez Villa, F ^a   De la Bellacasa, J Puig ^b   Moreno, A ^a   Cervera, C ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

Author keywords

Late onset opportunistic infection; Lymphopenia; PCP; Pneumocystis jirovecii; Rituximab; Solid organ transplantation

Indexed keywords

CALCINEURIN INHIBITOR; COTRIMOXAZOLE; CYCLOSPORIN A; EVEROLIMUS; IMMUNOGLOBULIN; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; TACROLIMUS; VALGANCICLOVIR; ANTIINFECTIVE AGENT;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BK VIRUS; BOLUS INJECTION; CARDIAC GRAFT REJECTION; CASE REPORT; CD4 LYMPHOCYTE COUNT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; CRACKLE; CYTOMEGALOVIRUS INFECTION; DRUG MEGADOSE; DYSPNEA; ENDOTRACHEAL INTUBATION; FEMALE; FEVER; FIBEROPTIC BRONCHOSCOPY; FOLLOW UP; GRAFT RECIPIENT; HEART TRANSPLANTATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPOXEMIA; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE UNIT; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; LUNG INFILTRATE; LUNG LAVAGE; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOPENIA; MALAISE; MALE; MEDICAL HISTORY; MIDDLE AGED; NONHUMAN; PANCREAS TRANSPLANTATION; PATIENT HISTORY OF HEART TRANSPLANTATION; PATIENT HISTORY OF KIDNEY TRANSPLANTATION; PERITONEAL DIALYSIS; PLASMAPHERESIS; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SECONDARY PREVENTION; TACHYPNEA; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REPLICATION; VOMITING; MICROBIOLOGY; ORGAN TRANSPLANTATION; PNEUMONIA, PNEUMOCYSTIS; TIME;

ADULT; ANTI-INFECTIVE AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; TIME FACTORS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 84897962280     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12184     Document Type: Article

References (29)

1. García-Gil D, Moreno A, Miró JM, et al. Pneumocystis carinii pneumonia in the transplant recipient. Enferm Infecc Microbiol Clin 1996; 14 (5): 296-299.
2. Martin SI, Fishman JA; AST Infectious Diseases Community of Practice. Pneumocystis pneumonia in solid organ transplantation. Am J Transplant 2013; 13 (Suppl 4): 272-279.
3. Fishman JA. Prevention of infection due to Pneumocystis carinii. Antimicrob Agents Chemother 1998; 42 (5): 995-1004.
4. Hughes WT. Current issues in the epidemiology, transmission, and reactivation of Pneumocystis carinii. Semin Respir Infect 1998; 13 (4): 283-288.
5. Sassi M, Ripamonti C, Mueller NJ, et al. Outbreaks of Pneumocystis pneumonia in 2 renal transplant centers linked to a single strain of Pneumocystis: implications for transmission and virulence. Clin Infect Dis 2012; 54 (10): 1437-1444.
6. Le Gal S, Damiani C, Rouillé A, et al. A cluster of Pneumocystis infections among renal transplant recipients: molecular evidence of colonized patients as potential infectious sources of Pneumocystis jirovecii. Clin Infect Dis 2012; 54 (7): e62-e71.
7. Arend SM, van't Wout JW. Editorial response: prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients - as long as the pros outweigh the cons. Clin Infect Dis 1999; 28 (2): 247-249.
8. Gordon SM, LaRosa SP, Kalmadi S, et al. Should prophylaxis for Pneumocystis carinii pneumonia in solid organ transplant recipients ever be discontinued? Clin Infect Dis 1999; 28 (2): 240-246.
9. Fishman JA. Prevention of infection caused by Pneumocystis carinii in transplant recipients. Clin Infect Dis 2001; 33 (8): 1397-1405.
10. Wang EH, Partovi N, Levy RD, Shapiro RJ, Yoshida EM, Greanya ED. Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of the past. Transpl Infect Dis 2012; 14 (5): 519-525.
11. Arend SM, Westendorp RG, Kroon FP, et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis 1996; 22 (6): 920-925.
12. Radisic M, Lattes R, Chapman JF, et al. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study. Transpl Infect Dis 2003; 5 (2): 84-93.
13. Reid AB, Chen SC, Worth LJ. Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools. Curr Opin Infect Dis 2011; 24 (6): 534-544.
14. Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation 1999; 68 (10): 1526-1532.
15. Neff RT, Jindal RM, Yoo DY, Hurst FP, Agodoa LY, Abbott KC. Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation 2009; 88 (1): 135-141.
16. Oz HS, Hughes WT. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J Infect Dis 1997; 175 (4): 901-904.
17. Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis 2009; 48 (6): 772-786.
18. Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. In human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004; 17 (4): 770-782.
19. Kamel S, O'Connor S, Lee N, Filshie R, Nandurkar H, Tam CS. High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone. Leuk Lymphoma 2010; 51 (5): 797-801.
20. Hugle B, Solomon M, Harvey E, et al. Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener's granulomatosis. Arthritis Care Res (Hoboken) 2010; 62 (11): 1661-1664.
21. Tsai MJ, Chou CW, Lin FC, Chang SC. Pneumocystis jiroveci pneumonia in patients with systemic lupus erythematosus after rituximab therapy. Lupus 2012; 21 (8): 914-918.
22. Stilling-Vinther MK, Pedersen BS. Fatal Pneumocystis jirovecii pneumonia following immunosuppressive therapy with rituximab and prednisolone for posterior scleritis. Acta Ophthalmol 2012; 90 (2): e154-e155.
23. Kamar N, Milioto O, Puissant-Lubrano B, et al. Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 2010; 10 (1): 89-98.
24. Shelton E, Yong M, Cohney S. Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection. Nephrology (Carlton) 2009; 14 (7): 696-699.
25. Kumar D, Gourishankar S, Mueller T, et al. Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient. Transpl Infect Dis 2009; 11 (2): 167-170.
26. Mansharamani NG, Balachandran D, Vernovsky I, Garland R, Koziel H. Peripheral blood CD4+ T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 2000; 118 (3): 712-720.
27. Overgaard UM, Helweg-Larsen J. Pneumocystis jiroveci pneumonia (PCP) in HIV-1-negative patients: a retrospective study 2002-2004. Scand J Infect Dis 2007; 39 (6-7): 589-595.
28. Muhammad Iqbal AH, Lim SK, Ng KP, Tan LP, Chong YB, Keng TC. Pneumocystis jirovecii pneumonia 13 years post renal transplant following a recurrent cytomegalovirus infection. Transpl Infect Dis 2012; 14 (4): E23-E26.
29. Kim T, Sung H, Lee YM, et al. No recurrence of Pneumocystis jirovecii pneumonia after solid organ transplantation regardless of secondary prophylaxis. Antimicrob Agents Chemother 2012; 56 (11): 6041-6043.